News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,444 Results
Type
Article (52218)
Company Profile (108)
Press Release (433107)
Multimedia
Podcasts (50)
Webinars (17)
Section
Business (129716)
Career Advice (1509)
Deals (18887)
Drug Delivery (80)
Drug Development (61241)
Employer Resources (102)
FDA (9889)
Job Trends (10387)
News (219490)
Policy (17977)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (2)
Academia (2739)
Academic (1)
Accelerated approval (33)
Adcomms (16)
Allergies (119)
Alliances (37112)
ALS (187)
Alzheimer's disease (1630)
Antibody-drug conjugate (ADC) (362)
Approvals (10154)
Artificial intelligence (515)
Autoimmune disease (219)
Automation (36)
Bankruptcy (131)
Best Places to Work (8294)
BIOSECURE Act (11)
Biosimilars (133)
Biotechnology (68)
Bladder cancer (126)
Brain cancer (58)
Breast cancer (588)
Cancer (4624)
Cardiovascular disease (331)
Career advice (1270)
Career pathing (37)
CAR-T (288)
CDC (32)
Celiac Disease (1)
Cell therapy (715)
Cervical cancer (25)
Clinical research (52029)
Collaboration (1762)
Company closure (1)
Compensation (405)
Complete response letters (45)
COVID-19 (2330)
CRISPR (95)
C-suite (871)
Cystic fibrosis (140)
Data (6211)
Decentralized trials (3)
Denatured (16)
Depression (119)
Dermatology (61)
Diabetes (411)
Diagnostics (4938)
Digital health (33)
Diversity (7)
Diversity, equity & inclusion (26)
Drug discovery (284)
Drug pricing (114)
Drug shortages (15)
Duchenne muscular dystrophy (197)
Earnings (49753)
Editorial (45)
Employer branding (15)
Employer resources (93)
Events (64792)
Executive appointments (839)
FDA (12476)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (7)
Frontotemporal dementia (25)
Funding (1352)
Gene editing (183)
Generative AI (45)
Gene therapy (511)
GLP-1 (711)
Government (3019)
Grass and pollen (3)
Guidances (345)
Healthcare (12989)
HIV (60)
Huntington's disease (37)
IgA nephropathy (68)
Immunology and inflammation (182)
Immuno-oncology (75)
Indications (138)
Infectious disease (2574)
Inflammatory bowel disease (166)
Inflation Reduction Act (9)
Influenza (102)
Intellectual property (228)
Interviews (288)
IPO (9003)
IRA (36)
Job creations (2344)
Job search strategy (1071)
JPM (37)
Kidney cancer (13)
Labor market (77)
Layoffs (373)
Leadership (21)
Legal (3156)
Liver cancer (61)
Longevity (22)
Lung cancer (593)
Lymphoma (339)
Machine learning (51)
Management (33)
Manufacturing (679)
MASH (148)
Medical device (7658)
Medtech (7707)
Mergers & acquisitions (10690)
Metabolic disorders (969)
mRNA (153)
Multiple sclerosis (188)
NASH (15)
Neurodegenerative disease (340)
Neuropsychiatric disorders (71)
Neuroscience (2884)
Neurotech (1)
NextGen: Class of 2026 (4193)
Non-profit (4326)
Now hiring (64)
Obesity (378)
Opinion (240)
Ovarian cancer (176)
Pain (165)
Pancreatic cancer (224)
Parkinson's disease (315)
Partnered (30)
Patents (418)
Patient recruitment (516)
Peanut (46)
People (41053)
Pharmaceutical (28)
Pharmacy benefit managers (15)
Phase 1 (17114)
Phase 2 (22639)
Phase 3 (16656)
Pipeline (6289)
Policy (218)
Postmarket research (2044)
Preclinical (8226)
Press Release (65)
Prostate cancer (231)
Psychedelics (33)
Radiopharmaceuticals (238)
Rare diseases (774)
Real estate (4097)
Recruiting (45)
Regulatory (15424)
Reports (37)
Research institute (2641)
Resumes & cover letters (236)
Rett syndrome (26)
RNA editing (12)
RSV (59)
Schizophrenia (145)
Series A (220)
Series B (146)
Service/supplier (10)
Sickle cell disease (91)
Special edition (19)
Spinal muscular atrophy (143)
Sponsored (38)
Startups (2579)
Stomach cancer (7)
Supply chain (64)
Tariffs (46)
The Weekly (34)
Vaccines (851)
Venture capital (68)
Weight loss (211)
Women's health (77)
Worklife (14)
Date
Today (95)
Last 7 days (540)
Last 30 days (2011)
Last 365 days (22169)
2026 (6856)
2025 (21943)
2024 (25050)
2023 (28959)
2022 (39039)
2021 (41581)
2020 (38259)
2019 (31888)
2018 (24100)
2017 (22432)
2016 (21986)
2015 (25802)
2014 (19281)
2013 (16689)
2012 (16707)
2011 (17503)
2010 (16176)
Location
Africa (620)
Alabama (85)
Alaska (3)
Arizona (156)
Arkansas (8)
Asia (30090)
Australia (5637)
California (8888)
Canada (2524)
China (1048)
Colorado (351)
Connecticut (411)
Delaware (234)
Europe (69882)
Florida (1394)
Georgia (285)
Hawaii (1)
Idaho (36)
Illinois (657)
India (67)
Indiana (435)
Iowa (21)
Japan (429)
Kansas (85)
Kentucky (31)
Louisiana (25)
Maine (23)
Maryland (1059)
Massachusetts (6417)
Michigan (236)
Minnesota (423)
Mississippi (3)
Missouri (96)
Montana (27)
Nebraska (19)
Nevada (78)
New Hampshire (42)
New Jersey (2545)
New Mexico (28)
New York (2438)
North Carolina (1256)
North Dakota (6)
Northern California (4413)
Ohio (266)
Oklahoma (17)
Oregon (23)
Pennsylvania (1637)
Puerto Rico (10)
Rhode Island (33)
South America (712)
South Carolina (42)
South Dakota (1)
Southern California (3589)
Tennessee (117)
Texas (1435)
United States (31526)
Utah (253)
Vermont (1)
Virginia (197)
Washington D.C. (61)
Washington State (803)
West Virginia (2)
Wisconsin (95)
Wyoming (1)
485,444 Results for "multiple myeloma research foundation mmrf".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
5 Therapies Moving the Multiple Myeloma Space Forward
A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told
BioSpace
. Here are five therapies that could change the treatment paradigm.
March 9, 2026
·
8 min read
·
Tristan Manalac
Cancer
FDA’s Multiple Myeloma Guidance Highlights Decade of Success
New draft guidance from the FDA on multiple myeloma endpoints reflects the new technology available to assess disease and how patient journeys have changed with better treatments.
January 30, 2026
·
4 min read
·
Dan Samorodnitsky
Opinion
Counteracting Complacency in Multiple Myeloma—We’re Not There Yet
Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must continue.
October 20, 2025
·
6 min read
·
Michael Andreini
Cancer
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed patients with multiple myeloma, regardless of eligibility for stem cell transplantation.
January 28, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
March 31, 2026
·
4 min read
FDA
J&J Wins Proactive FDA National Priority Voucher for Multiple Myeloma Combo
Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a Phase III study testing Tecvayli plus Darzalex in patients with relapsed or refractory multiple myeloma.
December 16, 2025
·
2 min read
·
Tristan Manalac
Approvals
J&J Wins Expansion for Top-Selling Cancer Drug in First for Smoldering Multiple Myeloma
Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of progression to active disease.
November 7, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma
April 15, 2026
·
2 min read
Press Releases
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
Clinical Trial Seeks to Validate Novel Blood-Based Assay that Predicts Relapse Risk by Analyzing the Biologic Behavior of Remaining Cancer Cells, Addressing Critical Gaps in Current Minimal Residual Disease (MRD) Testing
April 14, 2026
·
6 min read
Business
Multiple Myeloma Research Foundation (MMRF) Presents New Data from Multiple Myeloma Research Programs at the 21st International Myeloma Society Annual Meeting
September 25, 2024
·
5 min read
1 of 48,545
Next
